Loading
A phase 2 trial of Cemiplimab in cutaneous squamous cell carcinoma, run by Replimune, Inc., active and no longer recruiting.
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer is a phase 2 interventional study registered as NCT04050436 by Replimune, Inc., with 231 participants enrolled, started 2019-10-08 and due to reach its primary completion in 2025-09. Interventions recorded: Cemiplimab, RP1. Conditions listed: Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, Cutaneous squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, Cutaneous squamous cell carcinoma.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Replimune, Immune checkpoint inhibitors.
Shares Replimune, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, Cutaneous squamous cell carcinoma, Immune checkpoint inhibitors.